Skip to content

Serotonin research published in 2021

59 studies whose primary subject is serotonin were published in 2021, down from 62 in 2020. Newest first. Back to the serotonin overview

Studies

The Hallucinogenic Serotonin2A Receptor Agonist, 2,5-Dimethoxy-4-Iodoamphetamine, Promotes cAMP Response Element Binding Protein-Dependent Gene Expression of Specific Plasticity-Associated Genes in the Rodent Neocortex

Frontiers in Molecular Neuroscience December 24, 2021 Lynette A. Desouza, Madhurima Benekareddy, Sashaina E. Fanibunda et al. 46 citations

Psychedelic compounds that target the 5-HT 2A receptor are reported to evoke psychoplastogenic effects, including enhanced dendritic arborization and synaptogenesis. Transcriptional regulation of neuronal plasticity-associated genes is implicated in the cytoarchitectural effects of serotonergic psychedelics, however, the transcription factors that drive this regulation are poorly elucidated....

Overcoming Depression with 5-HT2A Receptor Ligands

International Journal of Molecular Sciences December 21, 2021 Agata Zięba, Piotr Stępnicki, Dariusz Matosiuk et al. 55 citations

Depression is a multifactorial disorder that affects millions of people worldwide, and none of the currently available therapeutics can completely cure it. Thus, there is a need for developing novel, potent, and safer agents. Recent medicinal chemistry findings on the structure and function of the serotonin 2A (5-HT2A) receptor facilitated design and discovery of novel compounds with...

DOI: 10.3390/ijms23010010 (opens in new tab) Virtual screening Receptor Depression economics Antidepressant +3

Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects

medRxiv December 17, 2021 Anders S. Olsen, Anders Lykkebo-Valløe, Brice Ozenne et al. 4 citations preprint

Abstract Background Psilocin, the neuroactive metabolite of psilocybin, is a serotonergic psychedelic that induces an acute altered state of consciousness, evokes lasting changes in mood and personality in healthy individuals, and has potential as an antidepressant treatment. Examining the acute effects of psilocin on resting-state dynamic functional connectivity implicates network-level...

Pharmacologic analysis of non-synonymous coding 5-HT2A SNPs reveals alterations psychedelic drug potencies and efficacies

bioRxiv Preprint Server December 9, 2021 Gavin P. Schmitz, Manish K. Jain, Samuel T. Slocum et al. preprint

Serotonin (5-Hydroxytryptamine; 5-HT) 2A receptor (5-HT2AR) signaling is essential for the actions of classical psychedelic drugs. In this study, we examined whether random sequence variations in the gene (single nucleotide polymorphisms, SNPs) encoding the 5-HT2AR affect the signaling of four commonly used psychedelic drugs. We examined the in vitro pharmacology of seven non-synonymous SNPs,...

Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review

Frontiers in Behavioral Neuroscience December 3, 2021 Michael Colla, Hanne Scheerer, Steffi Weidt et al. 9 citations

The serendipitous discovery of ketamine's antidepressant effects represents one of the major landmarks in neuropsychopharmacological research of the last 50 years. Ketamine provides an exciting challenge to traditional concepts of antidepressant drug therapy, producing rapid antidepressant effects seemingly without targeting monoaminergic pathways in the conventional way. In consequence, the...

Multimodal MRI data fusion reveals distinct structural, functional and neurochemical correlates of heavy cannabis use

Addiction Biology November 22, 2021 Dusan Hirjak, Mike M. Schmitgen, Florian Werler et al. 33 citations

Heavy cannabis use (HCU) is frequently associated with a plethora of cognitive, psychopathological and sensorimotor phenomena. Although HCU is frequent, specific patterns of abnormal brain structure and function underlying HCU in individuals presenting without cannabis-use disorder or other current and life-time major mental disorders are unclear at present. This multimodal magnetic resonance...

Molecular insights into psychedelic drug action

Journal of Neurochemistry November 19, 2021 Samuel T. Slocum, Jeffrey F. Diberto, Bryan L. Roth 59 citations

Abstract A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the...

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression

CNS Drugs November 17, 2021 Susan Ling, Felicia Ceban, Leanna M.W. Lui et al. 123 citations

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and...

Psychedelic medicines for mood disorders: current evidence and clinical considerations

Current Opinion in Psychiatry November 15, 2021 Jerome Sarris, Diego Pinzon Rubiano, Kimberley Day et al. 12 citations

Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent findings Serotonergic psychedelics have been found to modulate brain networks underlying various...

New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat.

Experimental Neurology November 1, 2021 Matteo Marti, Giuseppe Talani, Cristina Miliano et al. 6 citations

Methoxetamine (MXE) is a dissociative substance of the arylcyclohexylamine class that has been present on the designer drug market as a ketamine-substitute since 2010. We have previously shown that MXE (i) possesses ketamine-like discriminative and positive rewarding effects in rats, (ii) affects brain processing involved in cognition and emotional responses, (iii) causes long-lasting...

Serotonergic Psychedelics in Neural Plasticity

Frontiers in Molecular Neuroscience October 12, 2021 Kacper Łukasiewicz, Jacob J. Baker, Yi Zuo et al. 32 citations

Psychedelics, compounds that can induce dramatic changes in conscious experience, have been used by humans for centuries. Recent studies have shown that certain psychedelics can induce neural plasticity by promoting neurite growth and synapse formation. In this review, we focus on the role of classical serotonergic psychedelics in neural plasticity and discuss its implication for their...

5-HT2 Receptor Subfamily and the Halogen Bond Promise

Journal of chemical information and modeling October 7, 2021 A. Fierro, Douglas J. Matthies, B. Cassels et al.

The binding of C-4-halogenated 1-(4-X-2,5-dimethoxyphenyl)-2-aminopropane (DOX) serotonin agonist psychedelics at all three 5-HT2 receptor subtypes is up to two orders of magnitude stronger for X = Cl, Br, or I (but not F) than when C-4 bears a hydrogen atom and more than expected from their hydrophobicities. Our docking and molecular dynamics simulations agree with the fact that increasing the...

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

Translational Psychiatry October 2, 2021 Čestmír Vejmola, Filip Tylš, Václava Piorecká et al. 41 citations

Abstract Serotonergic psychedelics are recently gaining a lot of attention as a potential treatment of several neuropsychiatric disorders. Broadband desynchronization of EEG activity and disconnection in humans have been repeatedly shown; however, translational data from animals are completely lacking. Therefore, the main aim of our study was to assess the effects of tryptamine and...

The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies

Frontiers in Pharmacology September 29, 2021 João Castelhano, Gisela Lima, Marta Teixeira et al. 34 citations

There is an increasing interest in the neural effects of psychoactive drugs, in particular tryptamine psychedelics, which has been incremented by the proposal that they have potential therapeutic benefits, based on their molecular mimicry of serotonin. It is widely believed that they act mainly through 5HT2A receptors but their effects on neural activation of distinct brain systems are not...

Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis

Frontiers in Pharmacology September 16, 2021 Lukas A Basedow, Thomas Riemer, Simon Reiche et al. 16 citations

Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In...

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis

Journal of Psychopharmacology September 14, 2021 Robert F. Leger, Ellen M. Unterwald 54 citations

Background: Classical psychedelics are a group of drugs which act as agonists on the serotonin-2A (5-HT2A) receptor. Evidence suggests they may have a uniquely rapid and enduring positive effect on mood. However, marked heterogeneity between methodological designs in this emerging field remains a significant concern. Aims: To determine how differences in the type of psychedelic agent used and...

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review

Pharmaceuticals August 12, 2021 Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza et al. 30 citations

Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this...

Pharmacologic Similarities and Differences Among Hallucinogens

The Journal of Clinical Pharmacology August 1, 2021 Kristin Waters 18 citations

Abstract Hallucinogens constitute a unique class of substances that cause changes in the user's thoughts, perceptions, and mood through various mechanisms of action. Although the serotonergic hallucinogens such as lysergic acid diethylamide, psilocybin, and N,N‐ dimethyltryptamine have been termed the classical hallucinogens , many hallucinogens elicit their actions through other mechanisms...

The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative

International Journal of Molecular Sciences July 31, 2021 Karolina E. Kolaczynska, Jan Thomann, Marius C. Hoener et al. 35 citations

Pyrovalerone cathinones are potent psychoactive substances that possess a pyrrolidine moiety. Pyrovalerone-type novel psychoactive substances (NPS) are continuously detected but their pharmacology and toxicology are largely unknown. We assessed several pyrovalerone and related cathinone derivatives at the human norepinephrine (NET), dopamine (DAT), and serotonin (SERT) uptake transporters using...

DOI: 10.3390/ijms22158277 (opens in new tab) Cathinone Pharmacology Potency Dopamine transporter +4

The Potential Role of Serotonergic Hallucinogens in Depression Treatment

Life July 29, 2021 Dominika Psiuk, Emilia Nowak, Krystian Cholewa et al. 13 citations

Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic...